Trends in the use of implantable cardioverter-defibrillator and cardiac resynchronization therapy device in advancing age: Analysis of the Japan cardiac device treatment registry database

Hisashi Yokoshiki MD, PhD | Akihiko Shimizu MD, PhD | Takeshi Mitsuhashi MD, PhD | Kohei Ishibashi MD, PhD | Tomoyuki Kabutoya MD, PhD | Yasuhiro Yoshiga MD, PhD | Ritsuko Kohno MD, PhD | Haruhiko Abe MD, PhD | Akihiko Nogami MD, PhD

Members of the Implantable Cardioverter-Defibrillator (ICD) Committee of the Japanese Heart Rhythm Society

Abstract

Background: Trends of de novo implantation of cardiac implantable electronic devices (CIEDs) including implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy with a defibrillator (CRT-D) or pacemaker (CRT-P) in advancing age are unknown.

Methods: Analysis of data from the Japan cardiac device treatment registry (JCDTR) with an implantation date between January 2006 and December 2016 was performed focusing on advancing age of ≥75 years.

Results: The cohort included 17,564 ICD, 9,470 CRT-D and 1,087 CRT-P recipients for de novo implantation. The rate of patients ≥75 years of age increased from 17.1% to 20.5% in ICD implantation (P = .052), from 19.7% to 30.0% in CRT-D implantation (P < .0001), and from 40.0% to 64.0% in CRT-P implantation (P = .17). There was an apparent increase in the percentage of nonischemic patients aged ≥75 years receiving ICD (10.9% in 2006 to 16.4% in 2016, P = .0008) and CRT-D (17.1% in 2006 to 27.8% in 2016, P = .0001). The implantation for primary prevention ICD (P = .059) and CRT-D (P = .012) was also associated with a temporal increase in the percentage of patients aged ≥75 years.

Conclusions: Proportion of patients ≥75 years of age for de novo CIED implantation gradually increased from 2006 to 2016, presumably because of the growing number of nonischemic cardiomyopathy and heart failure patients requiring primary prevention of sudden cardiac death.
1 | INTRODUCTION

Implantable cardioverter-defibrillator (ICD) therapy has been proved to be effective for primary prevention of sudden cardiac death in patients with symptomatic heart failure with reduced ejection fraction (HFrEF).1-3 and its use is prevailing as one of the standard therapies in combination with guideline-directed medical therapy. Age of patients enrolled in randomized controlled trials was 65 ± 10 years old (means ± SD) in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II),3 60 years old (median) in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)3 and around 67 years old (median) in the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) study.2 On the other hand, the Amiodarone Trialists Meta-Analysis (ATMA) investigators demonstrated that sudden death to all-cause death ratio decreased with age, which was 51% in those age <50 years and 26% in those after age 80 years.4 Moreover, in nonischemic patients with HFrEF, the association between reduced all-cause mortality and ICD implantation became no significant with increasing age, and an optimal age cutoff for ICD implantation was present at ≦70 years.5

The United States (US) trends demonstrated that CRT-P use decreased progressively from 2002 (28.8% of all CRTs) to 2010 (15.2% of all CRTs) and that the percentage of CRTs (CRT-D and CRT-P) implanted in patients aged ≥85 years increased from 4.9% in 2003 to 8% in 2010.6 In CRT recipients without a prior history of sustained ventricular arrhythmias, advancing age was significantly associated with the choice of CRT-P over CRT-D in Japan, resulting that the mean age of those receiving CRT-P was 75 years old.7 This clinical practice could be reasonable because a defibrillator backup had subtle or no survival benefit in symptomatic heart failure patients requiring a CRT device in randomized controlled studies.2,8-9 However, Japanese trends in the age-stratified use of ICD and CRT device have not been evaluated.

This study was aimed at examining temporal trends of cardiac implantable electronic devices (CIEDs), including ICD/CRT-D/CRT-P, implantation by analyzing the Japan Cardiac Device Treatment Registry (JCDTR) database and to explore the hypothesis that there is an increasing number of CIEDs implanted in older patients aged ≥75 years over a decade in the recent aging society in Japan.

2 | METHODS

2.1 | Study population

The JCDTR was established in 2006 by the Japanese Heart Rhythm Society (JHRS) for a survey of actual conditions in patients undergoing de novo implantation of CIEDs including ICD/CRT-D/CRT-P.10-12 A new system, called New JCDTR, started on January 2019, in which data of patients at the implantation date after January 2018 are encouraged to register (https://membnew.jhrs.or.jp/newjcdtr/ accessed on March 1, 2020). The protocol for this research project has been approved by a suitably constituted Ethics Committee of each institution and it conforms to the provisions of the Declaration of Helsinki. This study analyzed the data of implantation date from 2006 to 2016 according to age of patients.

The Japan Arrhythmia Device Industry Association (JADIA) reports the annual number of de novo implantations of ICD and CRT-D from 2009 and that of CRT-P from 2015 (https://www.jadia.or.jp; Figure 1A). This study also evaluated the ratio of our registration to that reported in the JADIA (JCDTR/JADIA ratio).

2.2 | Statistical analysis

All data are expressed as mean ± SD. Simple between-group analysis was conducted using Student’s t test. Multiple comparisons were assessed by ANOVA with the post hoc analysis using a Bonferroni test when necessary. Categorical variables were compared using the Chi-square test. Differences with P < .05 were considered significant. Statview version 5.0 for Windows (SAS Institute Inc.) or R software version 3.2.3 (https://www.r-project.org/) was used for all statistical analyses.

3 | RESULTS

3.1 | Study cohorts

The JCDTR database constituted data of 28,121 patients who underwent de novo implantations of ICD, CRT-D or CRT-P from January 2006 to December 2016 (extracted on 29 September 2018). To be more specific, 17,564 ICD recipients, 9,470 CRT-D recipients and 1,087 CRT-P recipients were included for the evaluation (Table 1). With regard to age, gender, left ventricular ejection fraction (LVEF) and New York Heart Association (NYHA) class, there were significant differences among the three groups. The mean age of CRT-P recipients was 74.3 years old, which was higher than 60.8 years old of ICD recipients (P < .0001) and 66.9 years old of CRT-D recipients (P < .0001). The rate of ischemic heart disease was 36.4% in ICD recipients, which was highest among the three groups (P < .0001). The indication for defibrillation therapy was primary prevention in 66.7% of CRT-D recipients and in 25.6% of ICD recipients (P < .0001; Table 1). The rate of CRT (CRT-D and CRT-P) recipients without a prior history of sustained ventricular arrhythmias (ie, primary prevention of sudden cardiac death)
was 69.8% (not shown in Table 1). The number of registrations was maximum in 2011 which included 2007 patients with ICD, 1226 patients with CRT-D and 124 patients with CRT-P (Figure 1B).

Proportion of patients aged $\geq 75$ years and those $\geq 85$ years was 19.3% and 1.7% in all ICD implantations, 27.0% and 2.0% in all CRT-D implantations, and 59.0% and 13.0% in all CRT-P implantations (Figure 2). The distribution of advancing age for these CIEDs implantation was significantly different ($P < .0001$).

### 3.2 Age-stratified ICD/CRT-D/CRT-P implant trends

#### 3.2.1 Overall

In 2006, the percentage of ICD recipients and CRT-P recipients $\geq 75$ years of age was 17.1% and 40%. The rate increased to 20.5% for ICD recipients and 64.0% for CRT-P recipients in 2016, with a marginal significance ($P = .052$ for ICD, $P = .17$ for CRT-P; Figure 3A,C). There was a significant increase in the percentage of CRT-D recipients $\geq 75$ years of age from 19.7% in 2006 to 30.0% in 2016 ($P < .0001$). The percentage of CRT-D recipients $\geq 85$ years of age was 1.8% in 2006, and it increased to 3.5% in 2016 ($P = .0018$; Figure 3B). The percentage of all CRTs (CRT-D and CRT-P) implanted in patients aged $\geq 75$ years and those aged $\geq 85$ years was increased from 20% and 1.8% in 2006 to 36.7% and 5.8% in 2016, respectively ($P < .0001$ for the two age groups).

#### 3.2.2 Etiology: ischemic vs nonischemic

With regard to the etiology of heart diseases, there was a significant increase in the percentage of nonischemic patients $\geq 75$ years of age with ICD (10.9% in 2006 to 16.4% in 2016, $P = .0008$) and CRT-D (17.1% in 2006 to 27.8% in 2016, $P = .0001$) implantations. There was an increasing trend in nonischemic CRT-P recipients $\geq 75$ years of age, but with no statistical significance (25% in 2006 to 61.7% in 2016, $P = .22$). The rate of ischemic patients $\geq 75$ years of age changed with no statistical significance in ICD (28.0% in 2006 to 27.6% in 2016, $P = .87$), CRT-D (26.3% in 2006 to 35.3% in 2016, $P = .64$) and CRT-P (100% in 2006 to 70.5% in 2016) implantations (Figure 4).

#### 3.2.3 Indication: primary prevention vs secondary prevention

The percentage of secondary prevention ICD recipients and CRT-D recipients $\geq 75$ years of age was 18.5% and 21.5% in 2006, and
YOKOSHIKI et al. 20.5% and 22.0% in 2016. In contrast, there was a significant increase in the percentage of primary prevention CRT-D recipients ≥75 years of age (18.8% in 2006 to 33.6% in 2016, P = .012). There was an increasing trend in the percentage of primary prevention ICD recipients ≥75 years of age (13.1% in 2006 to 20.4% in 2016 for ICD, P = .059; Figure 5).

4 | DISCUSSION

The population of Japan decreased from 127.9 million in 2006 to 126.9 million in 2016, whereas the percentage of aged (≥75 years) people increased from 9.5% in 2006 to 13.3% in 2016 (https://www.stat.go.jp/data/jinsui/2016np). In accordance with this demographic change, this study demonstrated, with analyses of the JCDTR database, there has been a significant increase in the rate of de novo CIEDs implanted in patients with advancing age (ie, ≥75 years). Patients with nonischemic cardiomyopathy (but not ischemic cardiomyopathy) undergoing primary prevention CRT-D and ICD significantly contributed to the increase in the implantation of the aged (≥75 years) population.

An observation that the percentage of all CRTs (CRT-D and CRT-P) implanted in patients aged ≥85 years increased from 1.8% in 2006 to 5.8% in 2016 was similar to the situation in the US, but the proportion was less than that reported in the US (6.7% in 2006, 8.0% in 2010). The rate of primary prevention CRT-D implantation was 66.7% in this study (Table 1), which was lower than that of cohort studies in the US and Europe (72.4% in the US13 and 87% in Europe14). If symptomatic heart failure patients requiring a CRT device increase further and we opt to implant the device for primary prevention more frequently, the rate of CRT implantation in advancing age may become the same level as in the US.

In contrast to the higher prevalence of ischemic cardiomyopathy in the United States, about 70% of heart failure patients have nonischemic etiology in Japan (Table 1). In a subanalysis of the Cardiac Resynchronization – Heart Failure (CARE-HF), patients with ischemic cardiomyopathy showed a higher incidence of the primary outcome and worse prognosis, as compared to nonischemic cardiomyopathy. Therefore, the rate of ischemic patients of advancing age who have an indication for CRT-D may not be increasing to the same extent of nonischemic patients. In addition, there could be more comorbidities in ischemic patients, as they are generally

### TABLE 1 Characteristics of patients undergoing CIEDs implantation, stratified by device type

| Device | Number of patients | Age (y) | Male | Underlying heart disease | LVEF (%) | NYHA class |
|--------|--------------------|---------|------|--------------------------|----------|------------|
| ICD    | 17564              | 60.8 ± 15.4 | 13745 (78.2) | Ischemic | 6394 (36.4) | 50.0 ± 17.1 | I |
| CRT-D  | 9470               | 66.9 ± 11.2 | 7172 (75.7) | Nonischemic | 111170 (63.6) | 27.6 ± 9.2 | II |
| CRT-P  | 1087               | 74.3 ± 11.1 | 671 (61.7) | Primary prevention | 4502 (25.6) | 32.6 ± 11.3 | III |

Note: Values are means ± SD, or number (%).

Abbreviation: ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.

Patients without a prior history of sustained ventricular arrhythmias are defined as primary prevention.
relating to atherosclerosis in the whole body. A subanalysis of the MADIT II demonstrated reduced or lack of ICD benefit in patients with the highest comorbidities. This evidence may have precluded us from implanting CRT-D and ICD in ischemic patients ≥75 years with high comorbidities.

Based on the analysis of the JCDTR, determinants for selecting primary prevention CRT-D over CRT-P in patients with symptomatic HFrEF were younger age, male, reduced LVEF, a history of nonsustained ventricular tachycardia (NSVT). As expected, there was a remarkable disparity of age groups in ICD/CRT-D/CRT-P implanted patients, with the highest percentage of advancing age in CRT-P recipients (Figure 2). However, we do not have an appropriate answer regarding choice of CRT devices, ie, CRT-D or CRT-P, for HFrEF patients with a QRS duration ≥130 m/s and left bundle branch block (LBBB) QRS morphology without prior sustained ventricular arrhythmias. This is because randomized controlled trials that directly compare the effects of CRT-D and CRT-P on morbidity and mortality in such heart failure patients are scarce.

Several observational studies could not identify symptomatic heart failure patients who benefit more from CRT-D than CRT-P, as there were significant demographic and morbid differences between the two patient groups. Despite this, the superiority of CRT-D to CRT-P was reported in HFrEF patients with ischemic cardiomyopathy, those with nonischemic cardiomyopathy having left ventricular midwall fibrosis and those with the Goldenberg (MADIT) risk scores 0-2. More recently, CRT-D was not associated with prolonged survival especially in nonischemic cardiomyopathy and no previous history of ventricular arrhythmias, as compared to CRT-P. Besides, in systolic heart failure patients aged ≥75 years or ≥80 years, there was no significant difference in the risk of mortality between CRT-D and CRT-P groups after adjusting for baseline differences. Since (a)
CRT-Ds are larger and more expensive than CRT-Ps and (b) the predominant etiology of heart failure is nonischemic in Japan, we need to perform future research focusing on not only major cardiac events and mortality but also quality of life and cost-effectiveness in symptomatic heart failure patients undergoing CRT-D vs CRT-P especially in advancing age of \( \geq 75 \) years.

### 4.1 | Study limitations

There are several limitations to be considered in this study. First, clinical outcomes are not shown in this study, but we reported several outcomes in other studies.\(^{19,30}\) Second, the rate of registration with the JCDTR is decreasing as evident from the data of JADIA. For example, ratio of registration of the JCDTR to that of JADIA (JCDTR/JADIA ratio) was 57.0% for ICD and 49.3% for CRT-D in 2011, but it declined gradually. In 2016, the JCDTR/JADIA ratio was 33.6% for ICD, 32.6% for CRT-D and 21.1% for CRT-P (Figure 1B). The second version of JCDTR (New JCDTR) is now operative (https://membnew.jhrs.or.jp/newjcdtr/) and data of the implantation and follow-up in ICD/CRT-D/CRT-P implanted patients after January 2018 are prospectively enrolled. We hope the New JCDTR will be able to provide firm and further evidence of Japanese patients.

### 5 | CONCLUSIONS

There has been an apparent increase in the percentage of de novo ICD/CRT-D/CRT-P implanted in patients aged \( \geq 75 \) years in Japan. The implantation for primary prevention ICD and CRT-D as well as in nonischemic cardiomyopathy contributed to the temporal increase in CIED implantation in advancing age.

### ACKNOWLEDGEMENTS

We thank all the members of the JHRS who registered data in the JCDTR on a voluntary basis. As of 20 March 2020, 393 facilities in...
Japan had enrolled at least one patient. The list of the facilities that enrolled more than 100 patients (114 facilities in alphabetical order) is given below.

Akita Medical Center, Anjo Kosei Hospital, Bellland General Hospital, Dokkyo Medical University, Edogawa Hospital, Fujita Health University, Fukushima Medical University, Gifu Prefectural General Medical Center, Gifu University, Gunma University, Hiroasaki University, Hokkaido University Hospital, Hokko Memorial Hospital, Hyogo College of Medicine, IMS Katsushika Heart Center, Ishinomaki Red Cross Hospital, Itabashi Chuo Medical Center, JA Toyama Kouseiren Takaoka Hospital, Japanese Red Cross Society Kyoto Daini Hospital, Japanese Red Cross Wakayama Medical Center, JCHO Hokkaido Hospital, JCHO Kyushu Hospital, Jichi Medical University, Juntendo University, Juntendo University Urayasu Hospital, Kakogawa East City Hospital, Kamedo Medical Center, Kanazawa Medical University, Kansai Rosai Hospital, Keio University, Kitano Hospital, Kitasato University, Kochi Health Science Center, Kokura Memorial Hospital, Komaki City Hospital, Kumamoto Red Cross Hospital, Kumamoto University, Kurashiki Chuo Hospital, Kyorin University, Kyoto Prefectural University of Medicine, Kyoto-Katsura Hospital, Maebashi Red Cross Hospital, Matsudo City Hospital, Matsue Red Cross Hospital, Matsumoto Kyoritsu Hospital, Mie University, Mito Saiseikai General Hospital, Nagasaki University, Nagoya Tokushukai General Hospital, Nagoya University, Nara Medical University, National Hospital Organization Kagoshima Medical Center, National Hospital Organization Kanazawa Medical Center, National Hospital Organization Kyushu Medical Center, National Hospital Organization Shizuoka Medical Center, Nihon University, Niigata University, Nippon Medical University, Nippon Medical School Chiba Hokusou Hospital, Odawara Municipal Hospital, Okayama University, Okinawa Prefectural Chubu Hospital, Osaka City General Hospital, Osaka City University, Osaka Medical College, Osaka Police Hospital, Osaka Red Cross Hospital, Osaka University, Osaka Hospital Tokyo Heart Center, Saiseikai Central Hospital, Saiseikai Fukuoka General Hospital, Saiseikai Kumamoto Hospital, Saiseikai Shimonomori General Hospital, Saiseikai Yokohamashi Tobu Hospital, Saitama Red Cross Hospital, Sakakibara Memorial Hospital, Saku Central Hospital, Sakurabashi Watanabe Hospital, Seiei Hamamatsu General Hospital, Sendai Kosei Hospital, Shiga University of Medical Science, Shinshu University, Shizuoka Municipal Hospital, Showa General Hospital, Southern Tohoku General Hospital, St. Luke's International Hospital, St. Marianna University School of Medicine, Takeda Hospital, Tenri Hospital, The University of Tokyo, Toho University, Tokai University, Tokyo Medical University, Tokyo Metropolitan Bokutoh Hospital, Tokyo Metropolitan Hiroo Hospital, Tokyo Metropolitan Tama Medical Center, Tokyo Women's Medical University, Tottori University, Toyama Prefectural Central Hospital, Toyama University, Toyohashi Heart Center, Tsuchiura Kyodo General Hospital, Tsukuba Medical Center Hospital, University of Fukui, University of Miyazaki, University of Occupational and Environmental Health, University of Tsukuba, Ursaoe General Hospital, Yamaga Prefectural Central Hospital, Yamagata University, Yamaguchi University, Yamanashi Prefectural Central Hospital, Yokohama City University Hospital, Yokohama Rosai Hospital.

CONFLICTS OF INTEREST

The authors declare no conflict of interest related to this study.
REFERENCES

1. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37. Epub 2005/01/22.

2. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–50. Epub 2004/05/21.

3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83. Epub 2002/03/22.

4. Krahn AD, Connolly SJ, Roberts RS, Gent M. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. Am Heart J. 2004;147(5):837–40. Epub 2004/05/08.

5. Elming MB, Nielsen JC, Haarbo J, Videbæk L, Korup E, Signorovitch J, et al. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation. 2017;136(19):1772–80. Epub 2017/09/08.

6. Sridhar AR, Yarlagadda V, Parasa S, Reddy YM, Patel D, Lakireddy D, et al. Cardiac resynchronization therapy. Circulation. Arrhythmia and Electrophysiology. 2016;9(3):e003108. Epub 2016/02/28.

7. Yokoshiki H, Shimizu A, Mitsuhashi T, Furushima H, Sekiguchi Y, Manaka T, et al. Trends and determinant factors in the use of cardiac resynchronization therapy devices in Japan: analysis of the Japan cardiac device treatment registry database. J Arrhythmia. 2016;32(6):486–90. Epub 2016/12/07.

8. Gold MR, Daubert J-C, Abraham WT, Hassager C, Dinerman JL, Hudnall JH, et al. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circ Arrhythmia Elec. 2013;6(6):1163–8. Epub 2013/10/16.

9. Schuchert A, Muto C, Maounis T, Frank R, Bouligne E, Polauck A, et al. Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker. Europace. 2013;15(1):71–6. Epub 2012/08/29.

10. Shimizu A, Mihashi T, Furushima H, Sekiguchi Y, Manaka T, Nishii N, et al. Current status of cardiac resynchronization therapy with defibrillators and factors influencing its prognosis in Japan. J Arrhythmia. 2013;29:168–74.

11. Shimizu A, Nitta T, Kurita T, Imai K, Kimura T, Kobayashi Y, et al. Current status of implantable defibrillator devices in patients with left ventricular dysfunction - The first report from the online registry database. J Arrhythmia. 2008;24:133–40.

12. Shimizu A, Nitta T, Kurita T, Imai K, Kobayashi Y, Soejima K, et al. Actual conditions of implantable defibrillator therapy over 5 years in Japan. J Arrhythmia. 2012;28:263–72.

13. Lindvall C, Chatterjee NA, Chang Y, Chernack B, Jackson VA, Singh JP, et al. National trends in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator. Circulation. 2016;133(3):273–81. Epub 2015/12/05.

14. Marjon E, Leclercq C, Narayanan K, Boveda S, Klug D, Lacaze-Gadonneix J, et al. Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRiTuDe cohort study. Eur Heart J. 2015;36(41):2767–76. Epub 2015/09/04.

15. Yokoshiki H, Mitsuyama H, Watanabe M, Mitsuhashi T, Shimizu A. Cardiac resynchronization therapy in ischemic and non-ischemic cardiomyopathy. J Arrhythm. 2017;33(5):410–6. Epub 2017/10/13.

16. Wikstrom G, Blomstrom-Lundqvist C, Andre B, Lonnerholm S, Blomstrom P, Freemantle N, et al. The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. Eur Heart J. 2009;30(7):782–8. Epub 2009/01/27.

17. Goldenberg I, Yvas AK, Hall WJ, Moss AJ, Wang H, He H, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51(3):288–96. Epub 2008/01/22.

18. Reitan C, Chaudhry U, Bakos Z, Brandt J, Wang L, Platov NG, et al. Long-Term Results of Cardiac Resynchronization Therapy: A Comparison between CRT-Pacemakers versus Primary Prophylactic CRT-Defibrillators. Pacin Clin Electrophysiol. 2015;38(6):758–67. Epub 2015/03/20.

19. Yokoshiki H, Shimizu A, Mitsuhashi T, Furushima H, Sekiguchi Y, Manaka T, et al. Survival and heart failure hospitalization in patients with cardiac resynchronization therapy with or without a defibrillator for primary prevention in Japan—Analysis of the Japan cardiac device treatment registry database. Circ J. 2017. Epub 2017/06/20.

20. Barra S, Boveda S, Providencia R, Sadoul N, Duehmke R, Reitan C, et al. Adding defibrillation therapy to cardiac resynchronization therapy based on the basis of the myocardial substrate. J Am Coll Cardiol. 2017;69(13):1669–78. Epub 2017/04/01.

21. Kutyifa V, Geller L, Bogyi P, Zima E, Aktas MK, Ozcan EE, et al. Effect of cardiac resynchronization therapy with implantable cardioverter-defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience. Eur J Heart Fail. 2014;16(12):1323–30. Epub 2014/11/08.

22. Leyva F, Zegard A, Umar F, Taylor RJ, Acquaye E, Gubran C, et al. Long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation: impact of the aetiology of cardiomyopathy. Europace. 2018;20(11):1804–12. Epub 2018/04/27.

23. Witt CT, Kronborg MB, Nohr EA; Mortensen PT, Gerdes C, Jensen HK, et al. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy. Europace. 2016;18(3):413–9. Epub 2015/09/18.

24. Leyva F, Zegard A, Acquaye E, Gubran C, Taylor R, Foley PWX, et al. Outcomes of cardiac resynchronization therapy with or without defibrillation in patients with nonischemic cardiomyopathy. J Am Coll Cardiol. 2017;70(10):1216–27. Epub 2017/09/02.

25. Barra S, Looi KL, Gajendragadkar PR, Khan FZ, Virdee M, Agarwal S. Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy. Europace. 2016;18(8):1187–93. Epub 2015/11/15.

26. Barra S, Duehmke R, Providencia R, Narayanan K, Reitan C, Robucke T, et al. Very long-term survival and late sudden cardiac death in cardiac resynchronization therapy patients. Eur Heart J. 2019;40(26):2121–7. Epub 2019/05/03.

27. Saba S, McLaughlin T, He M, Althouse A, Mulukutla S, Hernandez I. Cardiac resynchronization therapy using pacemakers vs defibrillators in patients with nonischemic cardiomyopathy: The United States experience from 2007 to 2014. Heart Rhythm. 2019;16(7):1065–71. Epub 2019/04/21.

28. Munir MB, Althouse AD, Rijal S, Shah MB, Abu Daya H, Adelstein E, et al. Clinical characteristics and outcomes of older cardiac resynchronization therapy recipients using a pacemaker versus a defibrillator. J Cardiovasc Electrophysiol. 2016;27(6):730–4. Epub 2016/02/10.

ORCID
Hisashi Yokoshiki https://orcid.org/0000-0002-6247-2148
29. Laish-Farkash A, Bruoha S, Katz A, Goldenberg I, Suleiman M, Michowitz Y, et al. Morbidity and mortality with cardiac resynchronization therapy with pacing vs. with defibrillation in octogenarian patients in a real-world setting. Europace. 2017;19(8):1357–63. Epub 2016/10/14.

30. Yokoshiki H, Shimizu A, Mitsuhashi T, Furushima H, Sekiguchi Y, Manaka T, et al. Prognostic significance of nonsustained ventricular tachycardia in patients receiving cardiac resynchronization therapy for primary prevention: Analysis of the Japan cardiac device treatment registry database. J Arrhythm. 2018;34(2):139–47

How to cite this article: Yokoshiki H, Shimizu A, Mitsuhashi T, et al. Trends in the use of implantable cardioverter-defibrillator and cardiac resynchronization therapy device in advancing age: Analysis of the Japan cardiac device treatment registry database. J Arrhythmia. 2020;36:737–745. https://doi.org/10.1002/joa3.12377